TROG 99.02 - Anal Canal - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

Primary Sponsor

HeSANDA database for clinical trial data

21 April, 2025

Trial data-sharing made easier with HeSANDA initiative

Latest News: 21 April 2025 TROG Cancer Research is

16 April, 2025

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

LATEST NEWS: 15 April 2025 An innovative trial aimed

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases

TROG 99.02 – Anal Canal

A Prospective Single Arm Non Randomised Study of Concurrent Radiation and Chemotherapy For the Organ Conserving Treatment of Early Anal Canal Cancer

TROG 99.04/ALLG LY02 – Osteolymphoma – OL

ANZLG HD3/TROG 99.01 – Hodgkins Disease IFRT – HD3

Related Post

Trial data-sharing made easier with HeSANDA initiative

Mark Hughes Foundation grant for innovative SMART trial into brain metastases